Senior Accountant, Clinical

Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.

At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics.

As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality.

To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.

ESSENTIAL JOB FUNCTIONS:

• Oversee the monthly financial close process for clinical trials, including the preparation of journal entries and account reconciliations.
• Collaborate with Clinical Trial leadership to gather trial and project-related financial data, ensuring accurate and timely accruals.
• Prepare and maintain monthly balance sheet reconciliations for prepaid expenses, research and development (R&D) costs, and clinical trial accruals.
• Conduct monthly, quarterly, and annual variance analyses to support financial planning and reporting.
• Contribute to and maintain the ongoing compliance of Sarbanes-Oxley (SOX) internal control requirements, with a focus on clinical trial accruals.
• Support internal and external financial audits, walkthrough and testing, by preparing necessary documentation and financial schedules.
• Ensure financial reporting accuracy and compliance with Generally Accepted Accounting Principles (GAAP), SOX regulations, and company policies.
• Review and validate accounts payable invoices related to clinical trials.
• Assist in the implementation and optimization of accounting systems to enhance financial reporting efficiency.
• Participate in special projects and other finance-related initiatives as assigned to support departmental goals.

JOB SPECIFICATIONS:

• Bachelor’s degree in Accounting, Finance, or a related field, or equivalent work experience.
• 3 years of accounting experience, preferably within clinical research, healthcare, or life sciences.
• Experience in clinical trial accounting is preferred.
• Prior experience in a publicly traded company and the life sciences industry is a plus.
• Strong understanding of Generally Accepted Accounting Principles (GAAP) and financial reporting standards.
• Proficiency in financial reporting, reconciliations, and expense management.
• Experience with accounting software such as NetSuite, Blackline, Coupa, and Concur.
• Advanced proficiency in Microsoft Excel.
• Strong analytical and problem-solving abilities.
• Strong verbal and written communication skills.
• Exceptional attention to detail and organizational skills.
• Ability to work collaboratively in a team-oriented environment.
• Willingness to assist team members in achieving departmental goals and objectives.

The base range for this role is $94,000 to $104,000. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus.

#LI-RM1

Kura’s Values that are used for candidate selection and performance assessments:

• We work as one for patients
• We are goal-focused and deliver with excellence
• We are science-driven courageous innovators
• We strive to bring out the best in each other and ourselves

The Kura Package

• Career advancement/ development opportunities
• Competitive comp package
• Bonus
• 401K Employer contributions
• Generous stock options
• ESPP Plan
• 20 days of PTO to start
• 18 Holidays  (Including Summer & Winter Break)
• Generous Benefits Package with a variety of plans available with a substantial employer match
• Paid Paternity/Maternity Leave
• In-Office Catered lunches
• Home Office Setup
• Lifestyle Spending Stipend
• Commuter Stipend (Boston Office)
• Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more!

Kura Oncology is a clinical-stage biopharmaceutical company discovering and developing personalized therapeutics for the treatment of blood cancers and solid tumors. The company’s diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s approach to drug development is focused on rapidly translating novel science into life-saving medicines. Our goal is to help patients with cancer lead better, longer lives. Kura Oncology has offices in San Diego, California, and Boston, Massachusetts.

Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of R/R NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.

Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.